Amid the rise of psychedelics in the mental health space, researchers have begun to explore psilocybin as a potential treatment for chemotherapy-induced peripheral neuropathy. | Amid the rise of ...

Pfizer has found a new home for an antibody-drug conjugate it acquired in its $43 billion Seagen buyout and dropped earlier ...

Roche has decided to pay $190 million upfront for an unusual obesity mechanism after viewing preclinical data that “clearly ...

AbbVie released positive phase 3 data Thursday showing that its bispecific T-cell engager etentamig improved response rates ...

GSK is handing over $110 million upfront to Hutchmed in a deal worth up to $1.295 billion to get its hands on a ...

Ultragenyx had been flying high after its recent FDA approval for Genglycos—but the company has been brought back down to ...

Fortrea has agreed to acquire the early-phase services division of fellow CRO Worldwide Clinical Trials for $45 million. | Fortrea has agreed to acquire the early-phase services division of fellow CRO ...

Teva Pharmaceutical's dreams of a first-in-class autoimmune blockbuster are being kept alive after the Israeli outfit’s ...

TScan Therapeutics will reduce its workforce by 75% following the pause of its hematological and autoimmune programs. | TCR-T ...

The SEC and the FDA have signed a three-year agreement to step up cooperation and information-sharing capabilities aiming to ...

Novartis has struck a deal worth up to $3.2 billion to work with Alteogen on subcutaneous drug delivery, joining Biogen and ...

AI by itself isn’t enough to develop a compelling drug; the biology also has to check out. The science behind ABS-201 came to ...